Vera Therapeutics, Inc.

For the period ended Jun 30, 2026. Filed Aug 10, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 10, 2026

VERA$30.03-1.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Statements of Operations and Comprehensive Loss (unaudited)

Condensed Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

	Three Months EndedJune 30,		Six Months EndedJune 30,
	2026	2025	2026	2025
Operating expenses:
Research and development	$60,080	$58,195	$146,091	$99,473
General and administrative	52,410	21,946	91,531	37,862
Total operating expenses	112,490	80,141	237,622	137,335
Loss from operations	(112,490)	(80,141)	(237,622)	(137,335)
Other income (expense):
Interest income	5,348	6,320	11,703	13,226
Interest expense	(1,848)	(1,874)	(3,671)	(3,667)
Other expense, net	(483)	(836)	(915)	(449)
Total other income, net	3,017	3,610	7,117	9,110
Net loss	$(109,473)	$(76,531)	$(230,505)	$(128,225)
Other comprehensive loss:
Change in unrealized gains and losses on marketable securities	(247)	(127)	(1,189)	134
Comprehensive loss	$(109,720)	$(76,658)	$(231,694)	$(128,091)
Net loss per share attributable to common stockholders, basic and diluted	$(1.52)	$(1.20)	$(3.22)	$(2.01)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted	71,838,008	63,789,303	71,658,300	63,730,756

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.